ZIM
IMMU

Zacks Investment Management’s Immunomedics Inc IMMU Stock Holding History

Zacks Investment Management’s Portfolio IMMU Stock Details IMMU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-21,154
Closed -$750K – 586
2020
Q2 		$750K Buy
+21,154
New +$618K 0.02% 347

Other funds holding IMMU

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Zacks Investment Management's IMMU Position: Q3 2020 in Review

Zacks Investment Management sold out of Immunomedics Inc (IMMU) in Q3 2020, closing a stake of 21,154 shares — an estimated $750K sold.

Zacks Investment Management first reported a position in IMMU in Q2 2020 and held it in 1 quarter. The position peaked at $750K in Q2 2020. 408 funds tracked by Wall St. Rank hold IMMU as of Q3 2020.

  • Zacks Investment Management reported no remaining Immunomedics Inc position as of Q3 2020 after selling out during the quarter.
  • Zacks Investment Management sold 21,154 Immunomedics Inc shares in Q3 2020, an estimated $750K.
  • Zacks Investment Management first reported a position in Immunomedics Inc in Q2 2020 and held it in 1 quarter.
  • Zacks Investment Management's Immunomedics Inc position peaked at $750K in Q2 2020.
  • 408 funds tracked by Wall St. Rank held Immunomedics Inc as of Q3 2020.

Based on Zacks Investment Management's 13F filing for Q3 2020, filed 16 Nov 2020.